LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Начало・Списък с акции・Ovid therapeutics Inc

Ovid therapeutics Inc

Затворен

СекторЗдравеопазване

2.72 3.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.66

Максимум

2.75

Ключови измерители
By Trading Economics
Приходи	-27M -17M
EPS	-0.125
Марж на печалбата	-2,366.017
Служители	23
EBITDA	-5.5M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+95.24% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-19M 464M
Предишно отваряне	-0.31
Предишно затваряне	2.72

Настроения в новините

By Acuity

50%

138 / 344 Класиране в Healthcare

Ovid therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.05.2026 г., 23:08 ч. UTC

Придобивния, сливания и поглъщания

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29.05.2026 г., 20:53 ч. UTC

Печалби

Oil Declines Lift Stocks to Fresh Records -- WSJ

29.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 20:33 ч. UTC

Пазарно говорене

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29.05.2026 г., 20:11 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 19:47 ч. UTC

Печалби

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29.05.2026 г., 19:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29.05.2026 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29.05.2026 г., 18:19 ч. UTC

Пазарно говорене

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29.05.2026 г., 18:12 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29.05.2026 г., 18:11 ч. UTC

Пазарно говорене

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29.05.2026 г., 18:10 ч. UTC

Пазарно говорене

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29.05.2026 г., 17:55 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 17:55 ч. UTC

Пазарно говорене

NEAR Protocol Nearly Doubles in May -- Market Talk

29.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29.05.2026 г., 17:00 ч. UTC

Печалби

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

29.05.2026 г., 16:02 ч. UTC

Пазарно говорене

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29.05.2026 г., 15:40 ч. UTC

Пазарно говорене

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Canada's Economy Not Looking All That Bright -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ovid therapeutics Inc Прогноза

Ценова цел

By TipRanks

95.24% нагоре

12-месечна прогноза

Среден 5.33 USD 95.24%

Висок 7 USD

Нисък 4 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Ovid therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Ovid therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

138 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.